These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 19855306)

  • 1. Characterization of S-glutathionyl hemoglobin in homozygous sickle cell disease.
    Thom GG; Kallanagowdar C; Somjee SS; Velez MC; Yu LC; Hempe JM
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):895-900. PubMed ID: 19855306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectral analysis of asymmetric hemoglobin hybrids: demonstration of Hb FS (alpha2gammabetaS) in sickle cell disease.
    Ofori-Acquah SF; Green BN; Davies SC; Nicolaides KH; Serjeant GR; Layton DM
    Anal Biochem; 2001 Nov; 298(1):76-82. PubMed ID: 11673898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia.
    Odenheimer DJ; Sarnaik SA; Whitten CF; Rucknagel DL; Sing CF
    Am J Med Genet; 1987 Jul; 27(3):525-35. PubMed ID: 2443006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
    Segel GB; Simon W; Lichtman MA
    Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of radial immunodiffusion and alkaline cellulose acetate electrophoresis for quantitating elevated levels of fetal hemoglobin (HbF): application to evaluating patients with sickle cell disease treated with hydroxyurea.
    Schultz JC
    J Clin Lab Anal; 1999; 13(2):82-9. PubMed ID: 10102137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: implications for pharmacological intervention.
    Marcus SJ; Ware RE
    J Pediatr Hematol Oncol; 1999; 21(5):407-11. PubMed ID: 10524455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia.
    Lebensburger J; Johnson SM; Askenazi DJ; Rozario NL; Howard TH; Hilliard LM
    Am J Hematol; 2011 May; 86(5):430-2. PubMed ID: 21523807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea.
    Lapouméroulie C; Benkerrou M; Odièvre MH; Ducrocq R; Brun M; Elion J
    Haematologica; 2005 Mar; 90(3):401-3. PubMed ID: 15749673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheological properties of sickle erythrocytes in patients with sickle-cell anemia: The effect of hydroxyurea, fetal hemoglobin, and α-thalassemia.
    Ballas SK; Connes P;
    Eur J Haematol; 2018 Dec; 101(6):798-803. PubMed ID: 30204261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.